---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004810"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:26:32.982028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints

## Summary
- Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%
- Regenerative Solutions revenue rose 41% driven by Integrity implant outperformance (full-year 2024 surpassed in H1 2025)
- Hyalofast Phase III trial missed co-primary endpoints but showed statistically significant improvements in secondary endpoints; final PMA module on track for H2 2025
- Company reaffirms 2025 revenue/EBITDA guidance but revises long-term outlook for Hyalofast launch potential delay to 2027
- Operating expenses down 17% YoY; production yield issues resolved in June 2025 with no patient impact

## SEC filing metadata
- accession: 0001171843-25-004810
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/0001171843-25-004810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/f8k_073025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004810
- JSON: https://secwatch.observer/filing/0001171843-25-004810.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.